Risk stratification and medical therapy of pulmonary arterial hypertension
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 Time-course of completed randomised controlled trials (RCTs) in pulmonary arterial hypertension (PAH) (n=41) according to treatment strategy. SSc: systemic sclerosis; IPAH: idiopathic PAH. Reproduced and modified from [70] with permission.](https://figures.cochat.ai/paper-figures/44281cb9913845f29b53a42c8e3258e5/risk-stratification-and-medical-therapy-of-pulmonary-arterial-hypertension-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other high-risk profiles include familial PAH, PVOD, CTD-PAH, CTD-PAH associated with concomitant ILD, rapidly progressive disease despite therapy, and development of hemoptysis.(282, 291–293)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, the 2018 World Symposium on Pulmonary Hypertension strongly recommends serial parametric risk assessment.(282)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
The cited source says what the claim attributes to it.
In the citing paper
“The 2018 World Symposium on Pulmonary Hypertension states that the ultimate goal of therapy for patients with PAH is to achieve a low-risk status, assessed either by REVEAL or the ESC/ERS model.(282)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationBenza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Self-citationChannick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06250-x · Cited by 1,534
Self-citation
Research works printed but not linked: 2
- Benza, 2018, Comparison of three assessment strategies as predictors of one-year survival in US pulmonary arterial hypertension (PAH) patients, Am J Respir Crit Care Med, 197, A7649
- Galiè, 2014, AMBITION: a randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH), Eur Respir J, 44, 2916
Cited by
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Pulmonary Arterial Hypertension
Hassoun, P. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2000348 · Cited by 693
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review
Ruopp, N. F., & Cockrill, B. A. (2022) · JAMA · doi:10.1001/jama.2022.4402 · Cited by 643
An overview of the 6th World Symposium on Pulmonary Hypertension
Galiè, N., McLaughlin, V. V., Rubin, L. J., & Simonneau, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.02148-2018 · Cited by 526
Self-citationMultifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Hansmann, G., Koestenberger, M., Alastalo, T.-P., Apitz, C., Austin, E. D., Bonnet, D., Budts, W., D'Alto, M., Gatzoulis, M. A., Hasan, B. S., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.022 · Cited by 444
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
Hoeper, M. M., Pausch, C., Olsson, K. M., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., Gall, H., Distler, O., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02311-2021 · Cited by 349
Self-citationBenza, R. L., Kanwar, M. K., Raina, A., Scott, J. V., Zhao, C. L., Selej, M., Elliott, C. G., & Farber, H. W. (2021) · Chest · doi:10.1016/j.chest.2020.08.2069 · Cited by 341
Houston, B. A., Brittain, E. L., & Tedford, R. J. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2207410 · Cited by 280
Pulmonary Hypertension: A Brief Guide for Clinicians
Mandras, S. A., Mehta, H. S., & Vaidya, A. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.04.039 · Cited by 271
Treatment algorithm for pulmonary arterial hypertension
Chin, K. M., Gaine, S. P., Gerges, C., Jing, Z.-C., Mathai, S. C., Tamura, Y., McLaughlin, V. V., & Sitbon, O. (2024) · European Respiratory Journal · doi:10.1183/13993003.01325-2024 · Cited by 252
Self-citationThe physiological basis of pulmonary arterial hypertension
Naeije, R., Richter, M. J., & Rubin, L. J. (2022) · European Respiratory Journal · doi:10.1183/13993003.02334-2021 · Cited by 220
Boucly, A., Weatherald, J., Savale, L., de Groote, P., Cottin, V., Prévot, G., Chaouat, A., Picard, F., Horeau-Langlard, D., Bourdin, A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02419-2021 · Cited by 207
State-of-the-art evidence in the treatment of systemic sclerosis
Pope, J. E., Denton, C. P., Johnson, S. R., Fernandez-Codina, A., Hudson, M., & Nevskaya, T. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00909-5 · Cited by 206
Boucly, A., Savale, L., Jaïs, X., Bauer, F., Bergot, E., Bertoletti, L., Beurnier, A., Bourdin, A., Bouvaist, H., Bulifon, S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3698oc · Cited by 204
Poch, D., & Mandel, J. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202104200 · Cited by 187
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
Humbert, M. J. C., McLaughlin, V. V., Gibbs, J. S. R., Gomberg‐Maitland, M., Hoeper, M. M., Preston, I. R., Souza, R., Waxman, A. B., Ghofrani, H. A., Subías, P. E., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01347-2022 · Cited by 176
Self-citationThree- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Chin, K. M., Sitbon, O., Doelberg, M., Feldman, J., Gibbs, J. S. R., Grünig, E., Hoeper, M. M., Martin, N., Mathai, S. C., McLaughlin, V. V., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.057 · Cited by 171
Self-citationPortopulmonary hypertension in the current era of pulmonary hypertension management
Savale, L., Guimas, M., Ebstein, N., Fertin, M., Jevnikar, M., Renard, S., Horeau-Langlard, D., Tromeur, C., Chabanne, C., Prevot, G., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.021 · Cited by 170
Lewis, R. A., Johns, C., Cogliano, M., Capener, D. A., Tubman, E., Elliot, C. A., Charalampopoulos, A. F., Sabroe, I., Thompson, A. A. R., Billings, C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1771oc · Cited by 169
D’Alto, M., Badagliacca, R., Argiento, P., Romeo, E., Farro, A., Papa, S., Sarubbi, B., Russo, M. G., Vizza, C. D., Golino, P., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.09.009 · Cited by 167
Sleep-related breathing disorders and pulmonary hypertension
Adir, Y., Humbert, M. J. C., & Chaouat, A. (2020) · European Respiratory Journal · doi:10.1183/13993003.02258-2020 · Cited by 167
Current and future treatments of pulmonary arterial hypertension
Sommer, N., Ghofrani, H. A., Pak, O., Bonnet, S., Provencher, S., Sitbon, O., Rosenkranz, S., Hoeper, M. M., & Kiely, D. G. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15016 · Cited by 166
The 6th World Symposium on Pulmonary Hypertension: what’s old is new
Condon, D. F., Nickel, N. P., Anderson, R. J., Mirza, S., & Pérez, V. D. J. (2019) · F1000Research · doi:10.12688/f1000research.18811.1 · Cited by 166
Novel insights on the pulmonary vascular consequences of COVID-19
Potus, F., Mai, V., Lebret, M., Malenfant, S., Breton-Gagnon, É., Lajoie, A. C., Boucherat, O., Bonnet, S., & Provencher, S. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00195.2020 · Cited by 165
Hoeper, M. M., Al-Hiti, H., Benza, R. L., Chang, S.-A., Corris, P. A., Gibbs, J. S. R., Grünig, E., Jansa, P., Klinger, J. R., Langleben, D., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30532-4 · Cited by 159
Self-citationGrünig, E., MacKenzie, A., Peacock, A. J., Eichstaedt, C. A., Benjamin, N., Nechwatal, R., Ulrich, S., Saxer, S., Bussotti, M., Sommaruga, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa696 · Cited by 159
Self-citationTemporal trends in pulmonary arterial hypertension: results from the COMPERA registry
Hoeper, M. M., Pausch, C., Grünig, E., Staehler, G., Huscher, D., Pittrow, D., Olsson, K. M., Vizza, C. D., Gall, H. J., Distler, O., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02024-2021 · Cited by 159
Self-citationImaging of pulmonary hypertension in adults: a position paper from the Fleischner Society
Rémy‐Jardin, M., Ryerson, C. J., Schiebler, M. L., Leung, A. N. C., Wild, J. M., Hoeper, M. M., Alderson, P. O., Goodman, L. R., Mayo, J. R., Haramati, L. B., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04455-2020 · Cited by 136
BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
Lewis, R. A., Durrington, C., Condliffe, R. A., & Kiely, D. G. (2020) · European Respiratory Review · doi:10.1183/16000617.0009-2020 · Cited by 135
Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients
Levine, D. J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88609 · Cited by 133
Hemodynamics for the Heart Failure Clinician: A State-of-the-Art Review
Hsu, S., Fang, J. C., & Borlaug, B. A. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.012 · Cited by 130
Arvanitaki, A., Gatzoulis, M. Α., Opotowsky, A. R., Khairy, P., Dimopoulos, K., Diller, G., Giannakoulas, G. A., Brida, M., Griselli, M., Grünig, E., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.01.022 · Cited by 124
Self-citationEvaluation and management of pulmonary arterial hypertension
Beshay, S. M., Sahay, S., & Humbert, M. J. C. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106099 · Cited by 123
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Humbert, M. J. C., Farber, H. W., Ghofrani, H. A., Benza, R. L., Busse, D., Meier, C., & Hoeper, M. M. (2019) · European Respiratory Journal · doi:10.1183/13993003.02004-2018 · Cited by 121
Lindley, K. J., Merz, C. N. B., Asgar, A., Bello, N. A., Chandra, S., Davis, M. B., Gomberg‐Maitland, M., Gulati, M., Hollier, L. M., Krieger, E. V., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.026 · Cited by 116
Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society
Rémy‐Jardin, M., Ryerson, C. J., Schiebler, M. L., Leung, A. N. C., Wild, J. M., Hoeper, M. M., Alderson, P. O., Goodman, L. R., Mayo, J. R., Haramati, L. B., et al. (2021) · Radiology · doi:10.1148/radiol.2020203108 · Cited by 115
Chin, K., Rubin, L. J., Channick, R. N., Scala, L. D., Gaine, S., Galiè, N., Ghofrani, H. A., Hoeper, M. M., Lang, I. M., McLaughlin, V. V., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039360 · Cited by 109
Self-citationPulmonary Hypertension and Pregnancy
Martin, S., & Edwards, A. (2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003549 · Cited by 105
Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update
Coons, J. C., Pogue, K. T., Kolodziej, A., Hirsch, G. A., & George, M. P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1235-4 · Cited by 98
Lewis, R. A., Thompson, A. A. R., Billings, C., Charalampopoulos, A. F., Elliot, C. A., Hamilton, N., Hill, C., Hurdman, J. A., Rajaram, S., Sabroe, I., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00041-2020 · Cited by 96
Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia
Anderson, J., & Lau, E. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.04.008 · Cited by 94
Rosenkranz, S., Pausch, C., Coghlan, G., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., Gall, H. J., Distler, O., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.003 · Cited by 94
Self-citationKopeć, G., Kurzyna, M., Mroczek, E., Chrzanowski, Ł., Mularek‐Kubzdela, T., Skoczylas, I., Kuśmierczyk, B., Pruszczyk, P., Błaszczak, P., Lewicka, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010173 · Cited by 88
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension
Badagliacca, R., D’Alto, M., Ghio, S., Argiento, P., Bellomo, V., Brunetti, N. D., Casu, G., Confalonieri, M., Corda, M., Correale, M., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1006oc · Cited by 88
Dini, F. L., Pugliese, N. R., Ameri, P., Attanasio, U., Badagliacca, R., Correale, M., Mercurio, V., Tocchetti, C. G., Agostoni, P., Palazzuoli, A., et al. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10282-2 · Cited by 88
Guidelines for the Treatment of Pulmonary Arterial Hypertension
Vazquez, Z. G. S., & Klinger, J. R. (2020) · Lung · doi:10.1007/s00408-020-00375-w · Cited by 86
Avdeev, S. N., Барбараш, О. Л., Солтановна, В. З., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Владимирович, Г. В., Danilov, N. M., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6161 · Cited by 85
A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension
Ghio, S., Mercurio, V., Fortuni, F., Forfia, P. R., Gall, H. J., Ghofrani, H. A., Mathai, S. C., Mazurek, J. A., Mukherjee, M., Richter, M. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00513-2020 · Cited by 84
Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension
Calvier, L., Herz, J., & Hansmann, G. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.09.011 · Cited by 84
Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension
Rhodes, C. J., Wharton, J., Świetlik, E. M., Harbaum, L., Girerd, B., Coghlan, G., Lordan, J., Church, C., Pepke‐Żaba, J., Toshner, M. R., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202105-1118oc · Cited by 83
McGlothlin, D. P., Granton, J. T., Klepetko, W., Beghetti, M., Rosenzweig, E. B., Corris, P. A., Horn, E. M., Kanwar, M. K., McRae, K. M., Román, A., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.06.013 · Cited by 82
Self-citationBenza, R. L., Grünig, E., Sandner, P., Stasch, J., & Simonneau, G. (2024) · European Respiratory Review · doi:10.1183/16000617.0183-2023 · Cited by 80
Self-citationKuwana, M., Blair, C. J., Takahashi, T., Langley, J., & Coghlan, G. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216274 · Cited by 79
Sanada, T. J., Hosomi, K., Shoji, H., Park, J., Naito, A., Ikubo, Y., Yanagisawa, A., Kobayashi, T., Miwa, H., Suda, R., et al. (2020) · Pulmonary Circulation · doi:10.1177/2045894020929147 · Cited by 77
Pulmonary hypertension in connective tissue diseases, new evidence and challenges
Vonk, M. C., Vandecasteele, E. H., & van Dijk, A. P. J. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13453 · Cited by 75
Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment
Fauvel, C., Raitiere, O., Boucly, A., de Groote, P., Renard, S., Bertona, J., Lamblin, N., Artaud-Macari, É., Viacroze, C., Schleifer, D., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.005 · Cited by 75
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Sitbon, O., Chin, K., Channick, R. N., Benza, R. L., Scala, L. D., Gaine, S., Ghofrani, H. A., Lang, I. M., McLaughlin, V. V., Preiss, R., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.12.013 · Cited by 75
Self-citationKhanna, D., Zhao, C., Saggar, R., Mathai, S. C., Chung, L. S., Coghlan, G., Shah, M., Hartney, J. M., & McLaughlin, V. V. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41669 · Cited by 74
Self-citationHipertensión arterial pulmonar
Luna‐López, R., Martín, A. R., & Subías, P. E. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.01.003 · Cited by 72
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Weatherald, J. C., Bondeelle, L., Chaumais, M., Guignabert, C., Savale, L., Jaïs, X., Sitbon, O., Rousselot, P. H., Humbert, M. J. C., Bergeron, A., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00279-2020 · Cited by 72
Zelt, J. G. E., Sugarman, J. A., Weatherald, J. C., Partridge, A. C. R., Liang, J., Swiston, J. R., Brunner, N. W., Chandy, G., Stewart, D. J., Contreras-Domínguez, V., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.01552-2021 · Cited by 71
Diagnosis and Management of Pulmonary Hypertension in Patients With CKD
Walther, C. P., Nambi, V., Hanania, N. A., & Navaneethan, S. D. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.12.005 · Cited by 68
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
Sitbon, O., Cottin, V., Canuet, M., Clerson, P., Gressin, V., Perchenet, L., Bertoletti, L., Bouvaist, H., Picard, F., Prévôt, G., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00673-2020 · Cited by 68
Norvik, C., Westöö, C., Peruzzi, N., Lovrić, G., van der Have, O., Mokso, R., Jeremiasen, I., Brunnström, H., Galambos, C., Bech, M., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00103.2019 · Cited by 65
Thomas, C. A., Anderson, R. J., Condon, D. F., & Pérez, V. D. J. (2019) · Pulmonary Therapy · doi:10.1007/s41030-019-00105-5 · Cited by 65
United States Pulmonary Hypertension Scientific Registry
Badlam, J. B., Badesch, D. B., Austin, E. D., Benza, R. L., Chung, W. K., Farber, H. W., Feldkircher, K., Frost, A., Poms, A. D., Lutz, K. A., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.088 · Cited by 65
Self-citationHarnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension
Rhodes, C. J., Sweatt, A. J., & Maron, B. A. (2022) · Circulation Research · doi:10.1161/circresaha.121.319969 · Cited by 64
Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective
Sahay, S., Chakinala, M. M., Kim, N. H., Preston, I. R., Thenappan, T., & McLaughlin, V. V. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202405-0914so · Cited by 64
Self-citationPharmacotherapy for pulmonary arterial hypertension
Parikh, V. Y., Bhardwaj, A., & Nair, A. P. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.09.14 · Cited by 64
Noordegraaf, A. V., Channick, R. N., Cottreel, E., Kiely, D. G., Marcus, J. T., Martin, N., Моисеева, О. М., Peacock, A. J., Swift, A. J., Tawakol, A. A., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.07.027 · Cited by 64
Self-citationPulmonary Artery Denervation for Pulmonary Arterial Hypertension
Zhang, H., Wei, Y., Zhang, C., Yang, Z., Kan, J., Gu, H., Fan, F., Gu, H., Wang, Q., Xie, D., et al. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.09.013 · Cited by 63
Thoreau, B., & Mouthon, L. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103506 · Cited by 63
Vizza, C. D., Lang, I. M., Badagliacca, R., Benza, R. L., Rosenkranz, S., White, R. J., Adir, Y., Andreassen, A. K., Balasubramanian, V. P., Bartolome, S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2079pp · Cited by 63
Self-citationKariotis, S., Jammeh, E., Świetlik, E. M., Pickworth, J. A., Rhodes, C. J., Otero, P., Wharton, J., Iremonger, J., Dunning, M., Pandya, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27326-0 · Cited by 62
Avdeev, S. N., Барбараш, О. Л., Баутин, А. Е., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Danilov, N. M., Еременко, А. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4683 · Cited by 61
Kia, D. S., Kim, K., & Simon, M. A. M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.641310 · Cited by 59
Wu, X., He, Y., Chen, Z., He, Z.-Y., Yan, Y., He, Y., Wang, G., Dong, Y., Yang, Y., Sun, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37527-4 · Cited by 58
Self-citationKökény, G., Calvier, L., Legchenko, E., Chouvarine, P., Mozes, M. M., & Hansmann, G. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000580 · Cited by 57
Expert management of congenital portosystemic shunts and their complications
McLin, V. A., Franchi‐Abella, S., Brütsch, T., Bahadori, A., Casotti, V., de Goyet, J. D. V., Dumery, G., Gonzales, E. M., Guérin, F., Hascoët, S., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100933 · Cited by 56
Badagliacca, R., Papa, S., Matsubara, H., Lang, I. M., Poscia, R., Manzi, G., & Vizza, C. D. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.10.043 · Cited by 56
Hansmann, G., Meinel, K., Bukova, M., Chouvarine, P., Wåhlander, H., & Köestenberger, M. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.029 · Cited by 56
Gairhe, S., Awad, K. S., Dougherty, E. J., Ferreyra, G. A., Wang, S., Yu, Z., Takeda, K., Demirkale, C. Y., Torabi‐Parizi, P., Austin, E. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010206118 · Cited by 56
Lei, W., Chen, M., Huang, Z.-F., Chen, X.-Y., Wang, J., Zheng, J. J., Zhu, Y. Z., Lan, X., & He, Y. Z. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155376 · Cited by 55
Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension
Yogeswaran, A., Gall, H. J., Fünderich, M., Wilkins, M. R., Howard, L., Kiely, D. G., Lawrie, A., Hassoun, P. M., Sirenklo, Y., Torbas, O. O., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.03.018 · Cited by 55
Self-citationGerhardt, F., Fiessler, E., Olsson, K. M., Kayser, M. Z., Kovács, G., Gall, H. J., Ghofrani, H. A., Eslam, R. B., Lang, I. M., Benjamin, N., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.063821 · Cited by 55
Self-citationSystemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact
Naranjo, M., & Hassoun, P. M. (2021) · Diagnostics · doi:10.3390/diagnostics11050911 · Cited by 55
DuBrock, H. M. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.01.009 · Cited by 53
Quan, R., Zhang, G., Yu, Z., Zhang, C., Yang, Z., Tian, H., Yang, Y., Wu, W., Chen, Y., Liu, Y., et al. (2022) · Respirology · doi:10.1111/resp.14247 · Cited by 52
Atualização no Tratamento da Hipertensão Arterial Pulmonar
Fernandes, C. J. C. D. S., Calderaro, D., Assad, A. P. L., Salibe-Filho, W., Morinaga, L. T. K., Hoette, S., Piloto, B. M., Castro, M. A., Lisboa, R. P., da Silva, T. A. F., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200702 · Cited by 52
Comparison of Different Methods to Estimate Cardiac Index in Pulmonary Arterial Hypertension
Khirfan, G., Ahmed, M., Almaaitah, S., Almoushref, A., Agmy, G. M., Dweik, R. A., & Tonelli, A. R. (2019) · Circulation · doi:10.1161/circulationaha.119.041614 · Cited by 50
Young, A., Moles, V., Jaafar, S., Visovatti, S., Huang, S., Vummidi, D. R., Nagaraja, V., McLaughlin, V. V., & Khanna, D. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41732 · Cited by 49
Self-citationPregnancy and Pulmonary Hypertension
Mei, J. Y., Channick, R. N., & Afshar, Y. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.08.019 · Cited by 48
Self-citationHirani, N., Brunner, N. W., Kapasi, A., Chandy, G., Rudski, L., Paterson, D. I., Langleben, D., Mehta, S., & Mielniczuk, L. M. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.11.041 · Cited by 48
Knobler, R., Geroldinger‐Simić, M., Kreuter, A., Hunzelmann, N., Moinzadeh, P., Rongioletti, F., Denton, C. P., Mouthon, L., Cutolo, M., Smith, V. M., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19912 · Cited by 47
McLaughlin, V. V., Channick, R. N., Marco, T. D., Farber, H. W., Gaine, S., Galiè, N., Krasuski, R. A., Preston, I. R., Souza, R., Coghlan, G., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.10.043 · Cited by 47
Self-citationCytokines as prognostic biomarkers in pulmonary arterial hypertension
Boucly, A., Tu, L., Guignabert, C., Rhodes, C. J., de Groote, P., Prévôt, G., Bergot, E., BOURDIN, A. A., Beurnier, A., Roche, A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01232-2022 · Cited by 47
Hansmann, G., Calvier, L., Risbano, M. G., & Chan, S. Y. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0226ps · Cited by 46
Metadata
- Authors
- Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., & McLaughlin, V. V.
- Affiliations
- University of Bologna (IT)
- Harvard University (US)
- Mayo Clinic (US)
- University Hospital Heidelberg (DE)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tufts University (US)
- Houston Methodist (US)
- International University of Health and Welfare (JP)
- University of Michigan (US)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801889
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351343
- OpenAlex
- W2904385559
- Cited by
- 819
- References
- 88
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 101 · 2023: 108 · 2022: 174 · 2021: 169 · 2020: 128 · 2019: 58
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Funders
- Japan Society for the Promotion of Science (18K08183)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, risk stratification, medical therapy, combination therapy, treatment escalation, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues, right ventricular function, exercise capacity, one-year mortality, lung transplantation, treatment algorithm
- MeSH terms
- Pulmonary Arterial Hypertension, Calcium Channel Blockers, Humans, Randomized Controlled Trials as Topic, Lung Transplantation, Practice Guidelines as Topic, Risk Assessment, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.